The efficacy and safety of gemcitabine plus paclitaxel combination first-line therapy for Japanese patients with metastatic breast cancer including triple-negative phenotype

被引：0
|
作者：
Kenjiro Aogi
Masayuki Yoshida
Yoshiaki Sagara
Shunji Kamigaki
Minoru Okazaki
Jumpei Funai
Toshio Fujimoto
Masakazu Toi
Toshiaki Saeki
Shigemitsu Takashima
机构：
[1] Shikoku Cancer Center,Department of Breast Oncology
[2] Seirei Hamamatsu General Hospital,Department of Breast Surgery
[3] Sagara Hospital,Division of Breast Surgery
[4] Sakai Municipal Hospital,Department of Surgery
[5] Sapporo Breast Surgical Clinic,Science Communications
[6] Eli Lilly Japan K.K.,Medical Science
[7] Eli Lilly Japan K.K.,Department of Surgery
[8] Kyoto University Graduate School of Medicine,Department of Breast Oncology
[9] Saitama Medical University International Medical Center,undefined
[10] Shikoku Cancer Center,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2011年 / 67卷
关键词：
Anthracycline-pretreated metastatic breast cancer; Triple negative; Gemcitabine; Paclitaxel; Phase I/II trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1007 / 1015
页数：8
相关论文
共 50 条
  • [21] Economic Evaluation of Cisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine for the Treatment of First-Line Advanced Metastatic Triple-Negative Breast Cancer in China: Using Markov Model and Partitioned Survival Model
    Mingjun Rui
    Fenghao Shi
    Ye Shang
    Rui Meng
    Hongchao Li
    Advances in Therapy, 2020, 37 : 3761 - 3774
  • [22] Economic Evaluation of Cisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine for the Treatment of First-Line Advanced Metastatic Triple-Negative Breast Cancer in China: Using Markov Model and Partitioned Survival Model
    Rui, Mingjun
    Shi, Fenghao
    Shang, Ye
    Meng, Rui
    Li, Hongchao
    ADVANCES IN THERAPY, 2020, 37 (09) : 3761 - 3774
  • [23] Biomarker analysis of the LOTUS trial of first-line ipatasertib (IPAT) plus paclitaxel (PAC) in metastatic triple-negative breast cancer (TNBC)
    Wongchenko, Matthew J.
    Dent, Rebecca
    Kim, Sung-Bae
    Saura, Cristina
    Oliveira, Mafalda
    Baselga, Jose
    Kapp, Amy V.
    Chan, Wai Y.
    Singel, Stina M.
    Maslyar, Daniel J.
    Gendreau, Steven
    CANCER RESEARCH, 2018, 78 (04)
  • [24] Safety and efficacy of first-line docetaxel-gemcitabine in metastatic breast cancer
    不详
    EJC SUPPLEMENTS, 2006, 4 (02): : 168 - 168
  • [25] Updated survival data and biomarker assessment of the CBCSG006 trial: A randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer.
    Zhang, Jian
    Lin, Ying
    Hu, Xi-Chun
    Yang, Wentao
    Sun, Xiangjie
    Wang, Biyun
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [26] The safety and efficacy of durvalumab in combination with paclitaxel for the treatment of metastatic triple negative breast cancer
    Ghebeh, H.
    Alsayed, A. N.
    Suleman, K.
    Al-Tweigeri, T.
    ANNALS OF ONCOLOGY, 2018, 29
  • [27] nab-paclitaxel plus carboplatin or gemcitabine vs gemcitabine/carboplatin as first-line treatment for patients with triple-negative metastatic breast cancer: Results from the randomized phase 2 portion of the tnAcity trial
    Yardley, D.
    Coleman, R.
    Conte, P.
    Cortes, J.
    Brufsky, A.
    Shtivelband, M.
    Young, R.
    Bengala, C.
    Ali, H.
    Eakel, J.
    Schneeweiss, A.
    Merino, L. de la Cruz
    Wilks, S.
    O'Shaugnessy, J.
    Gluck, S.
    Li, H.
    Beck, R.
    Barton, D.
    Harbeck, N.
    CANCER RESEARCH, 2017, 77
  • [28] First-line Option for metastatic triple-negative Breast Cancer Live longer with new Immunotherapeutic Therapy
    Ruedesheim, Sabine M.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (1-2) : 69 - 69
  • [29] A phase Ill randomized trial of atezolizumab in combination with nab-paclitaxel as first line therapy for patients with metastatic triple-negative breast cancer (mTNBC)
    Emens, L.
    Adams, S.
    Loi, S.
    Schmid, P.
    Schneeweiss, A.
    Rugo, H.
    Chui, S.
    Winer, E.
    CANCER RESEARCH, 2016, 76
  • [30] Systemic corticosteroid use in patients with metastatic triple-negative breast cancer treated with first-line therapy in the United States
    Downer, M. K.
    Luhn, Patricia
    Miles, David
    Kent, Matthew
    Russell, Kenneth
    O'Shaughnessy, Joyce
    CANCER RESEARCH, 2020, 80 (04)
12345